Table 1. Sociodemographic, clinical, and laboratory characteristics and treatment outcomes of patients in the MDR/RR-TB cohort in Colombia, 2013–2015.
| Favorable n = | Unfavorable n = | pa | Bivariate A | Multivariate A | |||||
|---|---|---|---|---|---|---|---|---|---|
| 220 | % | 221 | % | ORcb | 95% IC | ORac | 95% IC | ||
| Age (years) | |||||||||
| < 20 | 24 | (61.5) | 15 | (38.5) | Refd | Ref | |||
| 20 to 39 | 95 | (51.1) | 91 | (48.9) | 0.236 | 1.5 | (0.8–3.1) | 1.8 | (0.8–3.8) |
| 40 to 59 | 82 | (48.8) | 86 | (51.2) | 0.154 | 1.6 | (0.8–3.4) | 1.6 | (0.7–3.5) |
| ≥60 | 19 | (39.6) | 29 | (60.4) | 0.043 | 2.4 | (1.1–5.8) | 2.7 | (1.1–6.8) |
| Sex | |||||||||
| Female | 88 | (65.4) | 68 | (43.6) | Ref | Ref | |||
| Male | 132 | (46.3) | 153 | (53.7) | 0.04 | 1.5 | (1.1–2.2) | 1.2 | (0.8–1.9) |
| Self-reported ethnicity | |||||||||
| Ethnicity, not referred | 171 | (47.9) | 186 | (52.1) | Ref | ||||
| Indigenous | 6 | (50.0) | 6 | (50.0) | 0.886 | 0.9 | (0.3–2.9) | ||
| Afro-Colombian | 43 | (59.7) | 29 | (40.3) | 0.069 | 0.6 | (0.4–1.0) | ||
| Form of tuberculosis | |||||||||
| Extrapulmonary | 19 | (55.9) | 15 | (44.1) | Ref | ||||
| Pulmonary | 201 | (49.4) | 206 | (50.6) | 0.468 | 0.8 | (0.4–1.6) | ||
| Health regime | |||||||||
| Contributive | 100 | (70.4) | 42 | (29.6) | Ref | Ref | |||
| Subsidized | 120 | (40.1) | 179 | (59.9) | <0.001 | 3.6 | (2.3–5.6) | 3.4 | (2.0–6.0) |
| Treating HCIe | |||||||||
| Private | 101 | (64.3) | 56 | (35.7) | Ref | Ref | |||
| Public | 117 | (42.5) | 158 | (57.5) | <0.001 | 2.4 | (1.6–3.7) | 1.2 | (0.7–2.0) |
| Level of care | |||||||||
| Primary | 165 | (53.4) | 144 | (46.6) | Ref | ||||
| Secondary and tertiary | 47 | (41.6) | 66 | (58.4) | 0.03 | 1.6 | (1.0–2.5) | ||
| Method used to diagnose resistance | |||||||||
| L.Jf Proportions | 20 | (44.4) | 25 | (55.6) | Ref | ||||
| Bactec MGITg | 97 | (50.0) | 97 | (50.0) | 0.502 | 0.8 | (0.4–1.5) | ||
| Lipah | 63 | (52.5) | 57 | (47.5) | 0.358 | 0.7 | (0.3–1.4) | ||
| Real-time PCRi | 40 | (48.8) | 42 | (51.2) | 0.640 | 0.8 | (0.4–1.7) | ||
| Type of resistance | |||||||||
| Monoresistance RMP j | 54 | (47.4) | 60 | (52.6) | Ref | Ref | |||
| XDRk | 2 | (14.3) | 12 | (85.7) | 0.032 | 4.2 | (0.8–20.6) | 4.5 | (0.9–22.6) |
| MDRl | 164 | (52.4) | 149 | (47.6) | 0.358 | 0.7 | (0.4–1.1) | 0.7 | (0.4–1.1) |
ap-value calculated by the chi-square test for favorable vs. unfavorable outcomes
bcrude odds ratio
cadjusted odds ratio
d reference
ehealth care institution
fLöwenstein-Jensen
gmycobacterial growth indicator
hline probe assay
ipolymerase chain reaction
jrifampicin
kextensive drug resistance
l multidrug resistance. The percentage reported is that of the rows. In the logistic regression model, the following variables were entered in a single step: health regime affiliation, type of resistance to rifampicin, treating HCI, level of care, age, and sex